SPECT/CT lymphoscintigraphy accurately localizes clipped and sentinel nodes after neoadjuvant chemotherapy in node-positive breast cancer

Placeholder

Publication Date

Advisor

Institution Author

Dilege, Ece
Çelik, Burak
Falay, Fikri Okan
Böge, Medine
Sucu, Serkan
Toprak, Safa
Ağcaoğlu, Orhan
Kapucuoğlu, Fatma Nilgün
Demirkol, Mehmet Onur

Co-Authors

Journal Title

Journal ISSN

Volume Title

Publisher:

Lippincott Williams & Wilkins
View PlumX Details

Abstract

PurposeThe aim of this study was to evaluate the impact of SPECT/CT lymphoscintigraphy on targeted axillary dissection (TAD) in node-positive breast cancer (BC) patients who had undergone neoadjuvant chemotherapy (NAC).MethodsSixty-two female BC patients with biopsy-confirmed axillary nodal metastases underwent NAC, followed by breast surgery with TAD. A metallic clip was placed in the sampled LN before NAC. On the day of surgery, a periareolar intradermal Tc-99m-nanocolloid injection was administered, followed by SPECT/CT lymphoscintigraphy. The clipped nodes were localized on CT images, assessed for Tc-99m uptake before surgery, and confirmed during the procedure.ResultsT1-4, N1-2 patients were enrolled in the study. All patients underwent sentinel lymph node (SLN) biopsy. The clipped node was the SLN in 54 (88.5%) patients. In 3 patients (4.9%), a clip was found in a nonsentinel lymph node. In 4 patients, the clips were not visible on SPECT/CT images, and lymph nodes were not found during the procedure. SPECT/CT correctly localized the clipped lymph node in all patients. The overall false-negative rate for TAD was 3.33%. The mean follow-up duration was 29 months, and there were no axillary recurrences.ConclusionsSPECT/CT lymphoscintigraphy can accurately localize clipped nodes and SLNs after NAC in patients with node-positive BC.

Description

Subject

Radiology, nuclear medicine and medical imaging

Citation

Endorsement

Review

Supplemented By

Referenced By

Copy Rights Note